<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04811079</url>
  </required_header>
  <id_info>
    <org_study_id>CR-6402</org_study_id>
    <nct_id>NCT04811079</nct_id>
  </id_info>
  <brief_title>The Role of Spectral Filtering in a Spectrally Adjustable Ocular Photosensitivity Analyzer</brief_title>
  <official_title>The Role of Spectral Filtering in a Spectrally Adjustable Ocular Photosensitivity Analyzer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 6-visit, single-center, non-dispensing, randomized, single-masked, 5Ã—5 crossover&#xD;
      study. Subjects will participate in 6 scheduled over the duration of approximately 10.5&#xD;
      months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Photosensitivity Threshold (VPT)</measure>
    <time_frame>at approximately 2-week follow-up</time_frame>
    <description>VPT will measured via the SAOPA instrument. VPT is the point at which a sensation of pain or discomfort occurs when the intensity of light is gradually increased from a low level. Subject's discomfort responses will be indicated via a button press. Testing is complete when 10 response reversals are acquired.</description>
  </primary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Photosensitivity</condition>
  <arm_group>
    <arm_group_label>Spectacle Filter Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(419nm, 437nm, 373nm, 456nm, 476nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spectacle Filter Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(437nm, 456nm, 419nm, 476nm, 373nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spectacle Filter Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(456nm, 476nm, 437nm, 373nm, 419nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spectacle Filter Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(476nm, 373nm, 456nm, 419nm, 437nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spectacle Filter Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(373nm, 419nm, 476nm, 437nm, 456nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spectacle Filter Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(476nm, 456nm, 373nm, 437nm, 419nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spectacle Filter Sequence 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(373nm, 476nm, 419nm, 456nm, 437nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spectacle Filter Sequence 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(419nm, 373nm, 437nm, 476nm, 456nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spectacle Filter Sequence 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(437nm, 419nm, 456nm, 373nm, 476nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 9.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spectacle Filter Sequence 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(456nm, 437nm, 476nm, 419nm, 373nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 10.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>419 nm Spectacle Filter</intervention_name>
    <description>TEST</description>
    <arm_group_label>Spectacle Filter Sequence 1</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 10</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 2</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 3</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 4</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 5</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 6</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 7</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 8</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>437 nm Spectacle Filter</intervention_name>
    <description>TEST</description>
    <arm_group_label>Spectacle Filter Sequence 1</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 10</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 2</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 3</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 4</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 5</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 6</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 7</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 8</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>456 nm Spectacle Filter</intervention_name>
    <description>TEST</description>
    <arm_group_label>Spectacle Filter Sequence 1</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 10</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 2</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 3</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 4</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 5</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 6</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 7</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 8</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>476 nm Spectacle Filter</intervention_name>
    <description>TEST</description>
    <arm_group_label>Spectacle Filter Sequence 1</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 10</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 2</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 3</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 4</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 5</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 6</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 7</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 8</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>373 nm Spectacle Filter</intervention_name>
    <description>CONTROL</description>
    <arm_group_label>Spectacle Filter Sequence 1</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 10</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 2</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 3</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 4</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 5</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 6</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 7</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 8</arm_group_label>
    <arm_group_label>Spectacle Filter Sequence 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Potential subjects must satisfy all of the following criteria to be enrolled in the&#xD;
             study:&#xD;
&#xD;
               1. The subject must read and sign the Informed Consent form.&#xD;
&#xD;
               2. The subject must appear able and willing to adhere to the instructions set forth&#xD;
                  in this clinical protocol.&#xD;
&#xD;
               3. Healthy adult males or females age â‰¥18 and â‰¤30 years of age.&#xD;
&#xD;
               4. Normal color vision as measured using the Ishihara 38-plate test.&#xD;
&#xD;
               5. Normal stereopsis as measured by a suitable test.&#xD;
&#xD;
               6. Auto-refraction must show a spherical component of -2.00 through +2.00 D, and a&#xD;
                  cylindrical component of 0.00 through 1.50 D.&#xD;
&#xD;
               7. The subject's distance refractive sphere must be between -2.00 and +2.00 D in&#xD;
                  each eye.&#xD;
&#xD;
               8. The subject's distance refractive cylinder must be â‰¤ 1.50 D in each eye.&#xD;
&#xD;
               9. The subject must have unaided distance Snellen visual acuity of 20/200 or better&#xD;
                  for each eye.&#xD;
&#xD;
              10. The subject must have best corrected distance Snellen visual acuity of 20/25 or&#xD;
                  better for each eye.&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
          -  Potential subjects who meet any of the following criteria will be excluded from&#xD;
             participating in the study:&#xD;
&#xD;
               1. Currently pregnant or lactating (subjects who become pregnant during the study&#xD;
                  will be discontinued).&#xD;
&#xD;
               2. History of refractive surgery or other ocular surgery.&#xD;
&#xD;
               3. Employee or immediate family member of an employee of clinical site (e.g.,&#xD;
                  Investigator, Coordinator, Technician).&#xD;
&#xD;
               4. Subjects that participated in the pilot study CR-6318.&#xD;
&#xD;
               5. Systemic conditions or the use of medications that the investigator believes will&#xD;
                  contraindicate participation in this study.&#xD;
&#xD;
               6. Abnormal Level 3 neuro-ophthalmology exam including crystalline lens clarity&#xD;
                  Grade 3 or worse (Lens Opacities Classification System).&#xD;
&#xD;
               7. Any Grade 3 or greater slit lamp findings (e.g., edema, corneal&#xD;
                  neovascularization, corneal staining, tarsal abnormalities, conjunctival&#xD;
                  injection) on the FDA Slit Lamp Classification Scale.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Vision Care, Inc. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Vision Care, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John R Buch, OD, MS, FAAO</last_name>
    <phone>1-800-843-2020</phone>
    <email>jbuch@its.jnj.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami Health - Bascom Palmer Eye Institute</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Photophobia</mesh_term>
    <mesh_term>Photosensitivity Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Johnson &amp; Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu</ipd_description>
    <ipd_url>http://yoda.yale.edu</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

